5 Dec 2022
Innovative Medicines Canada v. Canada (Attorney General)
Appellants challenged a regulation amending Patented Medicines Regulations, affecting pricing determination. Some amendments were repealed, while one challenge remains. The Federal Court found one section valid, and the appellate court agrees, dismissing the appeal. The challenge to changing comparator countries fails, deemed reasonable. The cross-appeal on additional factors and discounts is moot and dismissed. The appeal is dismissed with costs, and the cross-appeal is also dismissed as moot, without costs ordered.
